Key Points
- Fairmount Funds Management LLC director purchased 150,000 shares of Zenas BioPharma on March 31 at $20.00 per share ($3.0M), raising their stake to 2,359,025 shares (a 6.79% increase) — the trade was disclosed in an SEC filing.
- Despite institutional buying and a recent 5.4% stock uptick, Zenas reported a large quarterly miss (EPS of ($4.54) vs. consensus of ($1.22)); analysts are mixed with an average rating of "Hold" and an average price target of $44.14.
Zenas BioPharma, Inc. (NASDAQ:ZBIO - Get Free Report) Director Hongbo Lu bought 3,768 shares of the company's stock in a transaction on Tuesday, March 31st. The shares were acquired at an average price of $18.63 per share, for a total transaction of $70,197.84. Following the transaction, the director directly owned 426,736 shares in the company, valued at $7,950,091.68. This trade represents a 0.89% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.
Hongbo Lu also recently made the following trade(s):
- On Wednesday, February 11th, Hongbo Lu purchased 25,985 shares of Zenas BioPharma stock. The stock was acquired at an average cost of $22.50 per share, with a total value of $584,662.50.
Zenas BioPharma Stock Up 5.4%
ZBIO opened at $21.46 on Friday. The company has a debt-to-equity ratio of 0.32, a current ratio of 5.61 and a quick ratio of 5.61. Zenas BioPharma, Inc. has a 12 month low of $6.11 and a 12 month high of $44.60. The stock has a market capitalization of $1.23 billion, a P/E ratio of -2.75 and a beta of -0.54. The business has a 50 day simple moving average of $23.15 and a 200-day simple moving average of $27.22.
Zenas BioPharma (NASDAQ:ZBIO - Get Free Report) last announced its quarterly earnings data on Monday, March 16th. The company reported ($4.54) earnings per share for the quarter, missing analysts' consensus estimates of ($1.22) by ($3.32).
Institutional Investors Weigh In On Zenas BioPharma
Institutional investors and hedge funds have recently made changes to their positions in the business. GF Fund Management CO. LTD. acquired a new stake in Zenas BioPharma in the 4th quarter valued at about $38,000. Quarry LP raised its position in Zenas BioPharma by 34.5% during the third quarter. Quarry LP now owns 1,134 shares of the company's stock worth $25,000 after acquiring an additional 291 shares during the last quarter. Russell Investments Group Ltd. purchased a new stake in shares of Zenas BioPharma in the third quarter valued at about $30,000. CWM LLC grew its position in shares of Zenas BioPharma by 48.3% in the fourth quarter. CWM LLC now owns 2,178 shares of the company's stock valued at $79,000 after purchasing an additional 709 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Zenas BioPharma in the fourth quarter valued at approximately $95,000.
Wall Street Analyst Weigh In
ZBIO has been the topic of a number of research analyst reports. Wall Street Zen downgraded shares of Zenas BioPharma from a "hold" rating to a "strong sell" rating in a report on Saturday, March 21st. Guggenheim lifted their price target on shares of Zenas BioPharma from $45.00 to $55.00 and gave the company a "buy" rating in a research report on Monday, March 16th. Jefferies Financial Group reissued a "buy" rating and set a $48.00 price target on shares of Zenas BioPharma in a research note on Tuesday, January 6th. Wedbush restated an "outperform" rating and issued a $45.00 price target on shares of Zenas BioPharma in a report on Monday, December 22nd. Finally, Zacks Research downgraded Zenas BioPharma from a "hold" rating to a "strong sell" rating in a research note on Tuesday, March 17th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, Zenas BioPharma presently has an average rating of "Hold" and an average target price of $44.14.
View Our Latest Report on ZBIO
Zenas BioPharma Company Profile
(
Get Free Report)
Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company's proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.
Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
